Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Behrens

Showing results (101-110 of 119) with videos related to

Pageof 12
Sort By:
Clinical and Experimental Rheumatology|June 26, 2010
Interactions between rheumatologists and cardio-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosisDoerte Huscher, David Pittrow, Oliver Distler, et al.
The Journal of Rheumatology|December 4, 2009
Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS groupOtylia Kowal-Bielecka, Jerome Avouac, David Pittrow, et al.
The Lancet. Rheumatology|January 26, 2024
Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL BalancePeter Nash, Philip J Mease, Dona Fleishaker, et al.
RMD Open|February 22, 2024
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITALLaura C Coates, Robert Landewé, Iain B McInnes, et al.
Annals of the Rheumatic Diseases|February 19, 2014
MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trialFrank Behrens, Paul P Tak, Mikkel Østergaard, et al.
Annals of the Rheumatic Diseases|June 2, 2025
Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 studyPeter C Taylor, Philip J Mease, Kurt de Vlam, et al.
Lancet (London, England)|December 10, 2022
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)Joseph F Merola, Robert Landewé, Iain B McInnes, et al.
Talanta|October 22, 2023
Short-term predictor for COVID-19 severity from a longitudinal multi-omics study for practical application in intensive care unitsSabine Kugler, Lisa Hahnefeld, Jan Andreas Kloka, et al.
Biomedicines|October 27, 2022
Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic ArthritisRobert Gurke, Annika Bendes, John Bowes, et al.
Annals of the Rheumatic Diseases|April 30, 2015
PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locusJohn Bowes, Sabine Loehr, Ashley Budu-Aggrey, et al.
Pageof 12

Showing results (101-110 of 119) with videos related to

Sort By:
Pageof 12
Clinical and Experimental Rheumatology|June 26, 2010
Interactions between rheumatologists and cardio-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosisDoerte Huscher, David Pittrow, Oliver Distler, et al.
The Journal of Rheumatology|December 4, 2009
Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS groupOtylia Kowal-Bielecka, Jerome Avouac, David Pittrow, et al.
The Lancet. Rheumatology|January 26, 2024
Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL BalancePeter Nash, Philip J Mease, Dona Fleishaker, et al.
RMD Open|February 22, 2024
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITALLaura C Coates, Robert Landewé, Iain B McInnes, et al.
Annals of the Rheumatic Diseases|February 19, 2014
MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trialFrank Behrens, Paul P Tak, Mikkel Østergaard, et al.
Annals of the Rheumatic Diseases|June 2, 2025
Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 studyPeter C Taylor, Philip J Mease, Kurt de Vlam, et al.
Lancet (London, England)|December 10, 2022
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)Joseph F Merola, Robert Landewé, Iain B McInnes, et al.
Talanta|October 22, 2023
Short-term predictor for COVID-19 severity from a longitudinal multi-omics study for practical application in intensive care unitsSabine Kugler, Lisa Hahnefeld, Jan Andreas Kloka, et al.
Biomedicines|October 27, 2022
Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic ArthritisRobert Gurke, Annika Bendes, John Bowes, et al.
Annals of the Rheumatic Diseases|April 30, 2015
PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locusJohn Bowes, Sabine Loehr, Ashley Budu-Aggrey, et al.
Pageof 12